Dr. Robert Brodsky is a professor of medicine at the Johns Hopkins University School of Medicine. His area of clinical expertise is classical hematology and haploidentical bone marrow transplant for sickle cell disease and aplastic anemia. Dr. Brodsky serves as the director of the Division of Hematology and the T32 Training Program. He is the Johns Hopkins Family Professor of Medicine and Oncology. He received his M.D. from Hahnemann University. He completed his residency at the Vanderbilt University School of Medicine. He performed a fellowship in hematology at the National Institutes of Health and a fellowship in oncology at Johns Hopkins. He joined the Johns Hopkins faculty in 1997. From 2017 to 2022 he served as Associate Editor to The Journal of Clinical Investigation (JCI) and Secretary to American Society of Hematology (ASH). He serves as President of The American Society of Hematology (ASH) in 2023. Dr. Brodsky is rated as an Elite provider by MediFind in the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH). His top areas of expertise are Paroxysmal Nocturnal Hemoglobinuria (PNH), Paroxysmal Cold Hemoglobinuria, Anemia, Bone Marrow Transplant, and Splenectomy.

Dr. DeZern is a Professor of Oncology and Medicine at The Johns Hopkins University School of Medicine. She is active in the Division of Hematology Malignancies, Leukemia Program at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Dr. DeZern has expertise in aplastic anemia, myelodysplastic syndromes, paroxysmal nocturnal hemoglobinuria, acute myeloid leukemia, and bone marrow transplantation. Dr. DeZern received her medical degree at The Johns Hopkins University School of Medicine. She completed a residency in internal medicine at Johns Hopkins, followed by fellowships in medical oncology and hematology, as well as obtained a Masters in Clinical Investigations at the Bloomberg School of Public health. Dr. DeZern is a member of the American Society of Hematology, the American Society of Clinical Oncology, and the American Society for Transplantation and Cellular Therapy. Dr. DeZern’s principle research activities consist of designing and conducting clinical trials that test investigational new therapies and approaches in the treatment of bone marrow failure (aplastic anemia and myelodysplastic syndromes). She has specific expertise in the use of alternative donor bone marrow transplantation in patients with severe aplastic anemia and trials of novel therapeutics for patients with myelodysplastic syndromes. Additionally, she has taken a rigorous approach to the study of diagnostics and supportive case (such as transfusion practices) in these patient populations. She is or has been the Principal Investigator for a number of multicenter trials in collaboration with the MDS Clinical Research Consortium, the Eastern Co-operative Oncology Group (ECOG)-ACRIN and now the Bone Marrow Trials Clinical Trials Network (BMTCTN). She is the Study Chair for the multi-site BMTCTN study (CHAMP) investigating the role of haploidentical donor transplantation using post-transplantation cyclophosphamide in patients with relapsed several aplastic anemia. Dr. DeZern is the local PI as well as the Deputy Chair for The National MDS Study, a collaborative natural history study of the NHLBI and the NCI. As a clinical investigator with a focus on translation of novel treatments to the clinic, Dr. DeZern’s goal is to improve outcomes for patients with bone marrow failure at the bedside and in her research environment. Dr. Dezern is rated as a Distinguished provider by MediFind in the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH). Her top areas of expertise are Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML), Acute Myeloid Leukemia (AML), Bone Marrow Transplant, and Bone Marrow Aspiration.

Dr. Gloria F. Gerber is an Assistant Professor of Medicine at Johns Hopkins University in the Division of Hematology. She received her undergraduate degree in Biology with High. Dr. Gerber is rated as a Distinguished provider by MediFind in the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH). Her top areas of expertise are Paroxysmal Nocturnal Hemoglobinuria (PNH), Paroxysmal Cold Hemoglobinuria, Hemolysis, and Hemolytic Anemia.

Dr. Shruti Chaturvedi is an Associate Professor of Medicine at Johns Hopkins. She received her medical degree from Maulana Azad Medical College, University of Delhi, India. She then completed a residency in Internal Medicine at the Cleveland Clinic, Cleveland, OH, and a fellowship in Hematology and Oncology at Vanderbilt University, Nashville, TN. She has additionally obtained a Master of Science in Clinical Investigation (MSCI) degree from Vanderbilt University. Dr. Chaturvedi specializes in the care of adults with non-malignant hematologic disorders including thrombocytopenic purpura, atypical hemolytic uremic syndrome, antiphospholpiid syndrome, immune thrombocytopenia, autoimmune hemolytic anemia, thrombotic, other bleeding and clotting disorders, and anemias. Her research is focused on improving the care of patients with thrombotic microangiopathies with a focus on long term sequelae, and the role of complement in thrombotic disorders such as the antiphospholipid syndrome. Dr. Chaturvedi is rated as an Experienced provider by MediFind in the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH). Her top areas of expertise are Blood Clots, Atypical Hemolytic Uremic Syndrome (aHUS), Anemia, Splenectomy, and Bone Marrow Aspiration.

Dr. Howard Lederman is a professor of pediatrics at the Johns Hopkins University School of Medicine. He is the director of the Immunodeficiency Clinic, the Pediatric Immunology Laboratory, and the Ataxia-Telangiectasia (A-T) Clinical Center. Dr. Lederman specializes in the evaluation, diagnostic testing and long-term management of patients of all ages who have known or suspected primary immunodeficiency diseases. He is an expert on the use of gamma globulin therapy for a wide variety of disorders. After receiving his M.D. and Ph.D. from the University of Michigan, Dr. Lederman came to Johns Hopkins Children’s Center for a residency in pediatrics, followed by a fellowship in immunology at the Hospital for Sick Children in Toronto. Dr. Lederman’s current research laboratory and clinical research focuses on better understanding and treating patients with ataxia-telangiectasia, a devastating neurological disorder for which there is no cure. He is a member of numerous professional societies, including American Association of Immunologists, the American Society for Microbiology and the Clinical Immunology Society. Dr. Lederman is rated as an Experienced provider by MediFind in the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH). His top areas of expertise are Common Variable Immune Deficiency, X-Linked Agammaglobulinemia, Immunodeficiency with Hyper IgM Type 1, and Hyper IgE Syndrome.

Richard J. Jones, M.D., is a Professor of Oncology and Medicine, Director of the Bone Marrow Transplantation Program, and Co-Director of the Hematologic Malignancies Program at The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Dr. Jones received his Bachelor of Science in chemistry from Bucknell University prior to completing his medical degree at the Temple University School of Medicine. He then completed his residency at Temple University Hospital, where he was appointed to serve as Chief Resident in Internal Medicine. Dr. Jones later came to Johns Hopkins to complete his Medical Oncology Fellowship, and was then recruited to the faculty. Dr. Jones’ research is aimed at better understanding the biology of normal and cancer stem cells, with the goal of translating promising findings to the clinic particularly in the area of blood and marrow transplantation (BMT). Dr. Jones' laboratory discovered one the most commonly-used stem cell markers, Aldefluor which identifies cells based on their expression of aldehyde dehydrogenase 1 (ALDH1), and have used this marker to identify and characterize normal stem cells and cancer stem cells from many hematologic malignancies. This work also led to the development of post-transplant cyclophosphamide and effective related haploidentical BMT. Cyclophosphamide is metabolized by ALDH1, which is the reason both stem cells and memory lymphocytes are resistant to the drug. Recently, Dr. Jones' laboratory found that cytochrome P450 enzymes are a major mechanism by which the bone marrow stem cell niche protects both normal and leukemia stem cells. Dr. Jones co-leads the Hematologic Malignancies and Bone Marrow Transplantation Research Program. In addition to his promising work in the laboratory, Dr. Jones is recognized as a gifted mentor. During his tenure at Hopkins, he has trained a generation of leading physician-scientists who have excelled at Johns Hopkins and across the country. Dr. Jones has also authored numerous peer-reviewed articles that have been published in such prestigious journals as Blood, Nature, the New England Journal of Medicine, Lancet, PNAS, the Annals of Internal Medicine, the Journal of Clinical Oncology, the Journal of the National Cancer Institute, the British Journal of Haematology, and Leukemia. Dr. Jones is rated as an Experienced provider by MediFind in the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH). His top areas of expertise are Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Non-Hodgkin Lymphoma, Leukemia, and Splenectomy.

Dr. Rakhi P. Naik is the Associate Director for the Division of Hematology at Johns Hopkins University. She also serves as Director of the Fellowship Hematology Track and Director of Organ Systems Foundation of Medicine (OSFM), the largest pre-clerkship course in the medical school. She holds an undergraduate degree in Biomedical & Electrical Engineering from Duke University, an M.D. with. Dr. Naik is rated as an Experienced provider by MediFind in the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH). Her top areas of expertise are Sickle Cell Disease, Congenital Hemolytic Anemia, Hemolytic Anemia, and Hemoglobinopathy.

My clinical and research interests focus on disorders caused by telomere dysfunction. Our goal is to define approaches to surveillance, diagnosis and treatment for patients with telomere-mediated disease. Human syndromes associated with telomere shortening were first identified in the context of dyskeratosis congenita, a premature aging syndrome that predisposes to cancer. Dyskeratosis congenita patients and patients with telomere-mediated syndromes have an increased risk for developing certain malignancies which include myelodysplastic syndromes, myeloid leukemia and squamous cell carcinomas of the upper aerodigestive tract. The Telomere Clinic at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins provides multi-disciplinary care to patients who are suspected to have or who carry the diagnosis of telomere-related disorders. These disorders include individuals with cancer, bone marrow failure/aplastic anemia, lung disease including idiopathic pulmonary fibrosis and liver cirrhosis, among others. Our clinic brings together geneticists, genetic counselors, and we work closely with expert physicians in adult and pediatric hematology, bone marrow transplant, pulmonary medicine, lung transplant medicine, hepatology, and otolaryngology. Together, our team has established expertise in the management of these disorders and is at the forefront of leading the effort to individualize care for affected patients and their families. My group also has ongoing research efforts which include a long-term study to understand the genetics and spectrum of telomere disorders through a Registry which has been based at Johns Hopkins since 2005. Dr. Armanios is rated as an Experienced provider by MediFind in the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH). Her top areas of expertise are Pulmonary Fibrosis, Primary T Cell Immunodeficiency, Emphysema, and Ataxia-Telangiectasia.

Dr. Antoine Azar is an assistant professor of medicine at the Johns Hopkins University School of Medicine. His areas of clinical expertise include allergy and immunology, asthma, immunotherapy, sinusitis and drug reactions. Dr. Azar serves as the clinical director of the Division of Allergy and Clinical Immunology at Johns Hopkins. Dr. Azar earned his M.D. from the American University of Beirut. He completed residency programs at the University of Iowa Hospitals and Clinics and the American University of Beirut. He performed a fellowship in allergy and clinical immunology at the University of Iowa Hospitals and Clinics. Dr. Azar is rated as an Experienced provider by MediFind in the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH). His top areas of expertise are Primary Immunodeficiency (PID), Common Variable Immune Deficiency, Selective Deficiency of IgA, Adenoidectomy, and Endoscopy.

Thomas Traill is a Cardiologist in Baltimore,, Maryland. Dr. Traill is rated as an Experienced provider by MediFind in the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH). His top areas of expertise are Marfan Syndrome, Congenital Contractural Arachnodactyly, Arachnodactyly, and Bicuspid Aortic Valve.

Puneet Garcha is a Pulmonary Medicine specialist and a Transplant Surgeon in Baltimore, Maryland. Dr. Garcha is rated as an Experienced provider by MediFind in the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH). His top areas of expertise are Acute Interstitial Pneumonia, Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis, Lung Metastases, and Lung Transplant. Dr. Garcha is currently accepting new patients.

Maria Baer is a Hematologist Oncology specialist and a Hematologist in Baltimore, Maryland. Dr. Baer is rated as an Experienced provider by MediFind in the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH). Her top areas of expertise are Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Acute Promyelocytic Leukemia, Bone Marrow Aspiration, and Splenectomy. Dr. Baer is currently accepting new patients.

Ann Zimrin is a Hematologist Oncology specialist and a Hematologist in Baltimore, Maryland. Dr. Zimrin is rated as an Experienced provider by MediFind in the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH). Her top areas of expertise are Thrombocytopenia, Sickle Cell Disease, Hemoglobinopathy, Hemoglobin C Disease, and Splenectomy. Dr. Zimrin is currently accepting new patients.

Mark Gladwin is an Intensive Care Medicine specialist and a Pulmonary Medicine provider in Baltimore, Maryland. Dr. Gladwin is rated as an Experienced provider by MediFind in the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH). His top areas of expertise are Pulmonary Hypertension, Heart Failure with Preserved Ejection Fraction (HFpEF), Cerebral Hypoxia, Embolectomy, and Splenectomy.

Ami Patel is a Nephrologist in Baltimore, Maryland. Dr. Patel is rated as an Experienced provider by MediFind in the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH). Her top areas of expertise are Acute Kidney Failure, Nephrosclerosis, Renovascular Hypertension, and End-Stage Renal Disease (ESRD). Dr. Patel is currently accepting new patients.

Jennie Law is a Hematologist Oncology specialist and a Hospital Medicine provider in Baltimore, Maryland. Dr. Law is rated as an Experienced provider by MediFind in the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH). Her top areas of expertise are Sickle Cell Disease, Hemoglobinopathy, Hemoglobin SC Disease, Hemoglobin E Disease, and Bone Marrow Aspiration. Dr. Law is currently accepting new patients.

Heather Mannuel is an Oncologist and a Hematologist in Baltimore, Maryland. Dr. Mannuel is rated as an Experienced provider by MediFind in the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH). Her top areas of expertise are WT1-Related Wilms Tumor Syndromes, Chromophobe Renal Cell Carcinoma, Prostate Cancer, and Renal Cell Carcinoma (RCC). Dr. Mannuel is currently accepting new patients.

Evan Braunstein is a Hematologist Oncology specialist and a Hematologist in Baltimore, Maryland. Dr. Braunstein is rated as an Experienced provider by MediFind in the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH). His top areas of expertise are Myeloproliferative Neoplasms (MPN), Essential Thrombocythemia, Myelofibrosis, Sickle Cell Disease, and Bone Marrow Aspiration. Dr. Braunstein is currently accepting new patients.

Helen Byrnes is a Nurse Practitioner in Baltimore, Maryland. Ms. Byrnes is rated as an Experienced provider by MediFind in the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH). Her top areas of expertise are Small Lymphocytic Lymphoma (SLL), Myeloproliferative Neoplasms (MPN), Marginal Zone Lymphoma (MZL), and Smoldering Multiple Myeloma. Ms. Byrnes is currently accepting new patients.

Alison Moliterno is a Hematologist in Baltimore, Maryland. Dr. Moliterno is rated as an Experienced provider by MediFind in the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH). Her top areas of expertise are Myeloproliferative Neoplasms (MPN), Polycythemia Vera, Essential Thrombocythemia, Myelofibrosis, and Bone Marrow Aspiration. Dr. Moliterno is currently accepting new patients.